A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A
Aziz Eghbali, Peyman Eshghi, Gholamreza Toogeh, Samin Alavi, Zahra Badiei, Majid Ghanavat et al. A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A. // Annals of Hematology. – 2025. – DOI: 10.1007/s00277-025-06242-z. – URL: https://doi.org/10.1007/s00277-025-06242-z
Aziz Eghbali, Peyman Eshghi, Gholamreza Toogeh, Samin Alavi, Zahra Badiei, Majid Ghanavat, Mohammadreza Bordbar, Asghar Bazrafshan, Katayoon Karimi, Minoo Ahmadinejad, Araz Sabzvari, & Hamidreza Kafi (2025). A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A. Annals of Hematology. https://doi.org/10.1007/s00277-025-06242-z
Aziz Eghbali, et al. “A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A.” Annals of Hematology, 2025. doi:10.1007/s00277-025-06242-z.
@article{Eghbali2025,
title = {A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A},
author = {Eghbali, Aziz and Eshghi, Peyman and Toogeh, Gholamreza and Alavi, Samin and Badiei, Zahra and Ghanavat, Majid and Bordbar, Mohammadreza and Bazrafshan, Asghar and Karimi, Katayoon and Ahmadinejad, Minoo and Sabzvari, Araz and Kafi, Hamidreza},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06242-z},
url = {https://doi.org/10.1007/s00277-025-06242-z}
}